Coronary artery diseases (CAD) are the main cause of death worldwide. The reduction of these episodes has been possible through the right stratification of individuals to their cardiovascular risk and the reduction of classical factors such as high cholesterol levels, smoking or hypertension.
Identifying Patients at Cardiovascular Risk
Cardio inCode® is a prevention test for those individuals who have not suffered a coronary episode. It improves the use of known algorithms by including the genetic data of the patient.
Guidelines indicate that any individual with classical risk factors should be stratified. Those with family history of CAD, or that you consider at a higher risk of suffering a cardiac episode should be tested.
Cardio inCode® provides an overall personalized medicine solution to all these patients:Cardio inCode® Score may be used in patients who already have a classical risk factor such as hypertension, dyslipidemia, obesity, diabetes mellitus, thrombosis and degree of nicotine dependence. Cardio inCode® Score provides laboratory data on 11 SNPs (single nucleotide polymorphisms) associated with MI risk and independent of classical risk factors. This enables a more accurate and reliable CV risk assessment.
Cardio inCode® Check may be used in patients who do not have any classical risk factors yet or who wish to undergo a complete CV check-up. Cardio inCode® Check provides laboratory data on 11 independent risk SNPs, as well as on the 100 genetic variants for classical CV risk factors associated with relevant pathophysiological pathways such as hypertension, dyslipidemia, obesity, diabetes mellitus, thrombosis and degree of nicotine dependence.
Cardio inCode® provides clinicians with personalized genetic advice provided by a team of international experts, combining genetic information with clinical data and taking into account the patient's lifestyle.
Benefits of Cardio inCode® Testing
The Cardio inCode® test combines information from non-classical risk factors (genetic markers), with classical factors in known algorithms. This offers additional weight to reclassify patients, as demonstrated in population studies totalling about 6,000 individuals (including the Framingham cohort).
Medical Management of Patients with Increased Cardiovascular Risk
According to European and American guidelines, patients at the intermediate cardiovascular risk category can have therapeutic interventions through the use of statins and anti-hypertensives. High risk patients would go through therapeutic intervention.
What is the unique advantage of the Cardio inCode ® test from Ferrer inCode?
Genetic biomarkers reveal more information regarding the real cardiovascular risk of the patient, instead of using only cholesterol levels, blood pressure, glucose concentration, and if the person is a smoker.
Cardio inCode® FAQs
[accordion][accordion-item title="How do I order a test?"]Please contact us and let us know if you would like to order a test for a patient. One of our representatives will get in touch with you and advise on the workflow, and provide the necessary forms and sample collection kits. Once the samples have been collected, we will coordinate the shipment of the sample to the laboratory. Once testing is completed, the report will be sent to you.[/accordion-item][accordion-item title="How is Cardio inCode® performed?"]Patient saliva sample is used. [/accordion-item] [accordion-item title="How long does it take for Cardio inCode® results?"]Test results can be obtained in three to four weeks.[/accordion-item] [/accordion] [accordion] [accordion-item title="What does a Cardio inCode® result reveal to a patient?"] The 10-year risk category based on the known clinical algorithms (Framingham, Score, Regicor). [/accordion-item] [/accordion]